Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Its facilities and services are classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers. In which Acute inpatient psychiatric facilities contribute the majority of revenue in the United States. The Company has one reportable segment, behavioral healthcare services. The behavioral healthcare services segment provides inpatient and outpatient behavioral healthcare services.
Last trade$38.04
Day change-$0.665 (-1.72%)
Day range$36.77 – $39.06
Volume656,633
Market cap$3.60B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.6B
Price / earnings
—
Price / book
1.78×
Price / sales
1.05×
EV / sales
1.7×
EV / EBITDA
10.82×
Profitability
Earnings per share
-$12.13
Return on assets
-20.31%
Return on equity
-55.77%
Dividend yield
0.12%
Liquidity and leverage
Debt / equity
1.16×
Current ratio
1.6×
Quick ratio
1.6×
Cash ratio
0.3×
Cash flow
Price / cash flow
15.3×
Price / free cash flow
—
Free cash flow
-$23.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACHC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$895.31M
$865.84M
$828.8M
$821.46M
$851.57M
$869.23M
$770.51M
$774.24M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$895.31M
$865.84M
$828.8M
$821.46M
$851.57M
$869.23M
$770.51M
$774.24M
Selling, general and administrative
$548.93M
$529.86M
$520.24M
$509.18M
$513.65M
$502.38M
$490.98M
$473.07M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$801.37M
$785.43M
$780.73M
$945.04M
$774.97M
$728.38M
$726.59M
$688.88M
Operating income
$93.94M
$80.41M
$48.07M
-$123.58M
$76.6M
$140.85M
$43.92M
$85.36M
Interest expense
-$37.28M
-$38.18M
$0
-$37.93M
-$36.62M
-$35.14M
$0
-$30.07M
Income before taxes
$56.47M
$22.01M
$10.96M
-$1.17B
$39.99M
$50M
$13.47M
$38.01M
Income taxes
$17.82M
$9.75M
$6.5M
$7.84M
$1.67M
$12.07M
$4.4M
$4.48M
Net income
$38.65M
$12.26M
$4.46M
-$1.18B
$38.32M
$37.94M
$9.06M
$33.53M
Net income attributable to common shareholders
$34.49M
$10.93M
$4.11M
-$1.18B
$36.25M
$30.13M
$8.37M
$32.62M
EBITDA
$167.2M
$138.2M
$136.26M
$93.4M
$166.99M
$191.3M
$125.53M
$143M
Basic earnings per share
$0.38
$0.12
$0.05
-$13.02
$0.40
$0.33
$0.09
$0.36
Diluted earnings per share
$0.38
$0.12
$0.05
-$13.12
$0.40
$0.33
$0.09
$0.35
Recent news
Company coverage with links to the original publishers.
The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF launched in 2011 with $240.63 million in assets. It offers low costs (0.35% expense ratio), diversified exposure across 63 holdings, and has gained 36.18% year-to-date and 43.08% over the past year. With a beta of 0.93 and Zacks ETF Rank of 3 (Hold), it represents a reasonable option for healthcare sector exposure, though it carries medium risk.
IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.
Acadia Healthcare (ACHC) is highlighted as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of B. The stock has significantly outperformed its industry and the broader market, rising 23.5% over the past week, 28.7% over the past quarter, and 112.49% over the past year. Positive earnings estimate revisions over the past two months support the bullish outlook.
Acadia Healthcare reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.46, with revenues of $895.31 million exceeding expectations by 3%. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Medical-Hospital industry ranks in the bottom 7% of Zacks industries, which could limit future stock performance despite the company's strong year-to-date gains of 108.7%.
Edwards Lifesciences is expected to report Q3 2026 results on November 4 with revenues of $1.68 billion (+8% YoY) and EPS of 73 cents (+9% YoY). The company's TAVR segment is projected to grow 35% YoY driven by procedural growth and new clinical approvals, while TMTT is expected to grow 5.1% YoY. Edwards has a positive Earnings ESP of +0.76% and Zacks Rank #3, suggesting potential for beating estimates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.